Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | CPA3 | P15088 | 3/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | BMP1 | P13497 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900013 | 0.85 | HDAC1 (0.44) | BMP1 | |
| SCHEMBL5052372 | 0.79 | CYP1A2 (0.68) | CYP1A2EPHX1CPA3SLC1A3SLC1A2 | |
| SCHEMBL3699986 | 0.79 | EPHX1 (0.53) | EPHX1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3771287 | 0.79 | EPHX1 (0.53) | EPHX1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7386471 | 0.79 | MME (0.62) | BMP1MMP12ALDH1A1 | |
| SCHEMBL7386469 | 0.79 | MME (0.62) | BMP1MMP12ALDH1A1 | |
| SCHEMBL7386474 | 0.79 | MME (0.62) | BMP1MMP12ALDH1A1 | |
| SCHEMBL3895767 | 0.79 | PNMT (0.42) | — | |
| SCHEMBL3899341 | 0.78 | ADRA2A (0.38) | — | |
| SCHEMBL5091424 | 0.77 | MME (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615629-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | claimed |
| US-7375120-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | claimed |
| US-20060229341-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2006-10-12 | — | — | US | claimed |
| EP-1615629-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7375120-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1615629-A4 | PEPTIDE DEFORMYLASE INHIBITORS | CHRISTENSEN SIEGFRIED B IV (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20060229341-A1 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC | 2006-10-12 | — | — | US | disclosed |
| EP-1615629-A1 | PEPTIDE DEFORMYLASE INHIBITORS | Christensen, Siegfried B. IV (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004098584-A1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229341-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | CYP1A2 4681/4885EPHX1 3547/4885CPA3 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.